Thank you for donating!

You can donate using the following services.

Posts filed in: "Clinical Trials"

  1. 12.03.21

    Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference

    Read more
  2. 10.03.21

    Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

    We are pleased to share the following update from Cyclo Therapeutics entitled 'Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer'...

    Read more
  3. 09.03.21

    Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

    We are pleased to share the latest update from Cyclo Therapeutics entitled: Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™...

    Read more
  4. 04.03.21

    Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™...

    Read more
  5. 01.03.21

    Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer

    Read more